Through primary research, Acadia Strategy Partners gives growing biotech and gene therapy companies and their investors the insights and color commentary they need to make complex commercialization decisions.
At Acadia Strategy Partners, we uncover insights by talking with those who know the market best. Where all these perspectives converge, an instructive and validated narrative emerges, revealing fertile ground among the unproven frontier.
Clinical Experts
Patients
Payors
Wall Street
Competitors
Our researchers have worked with companies across every stage of rare disease drug development, as well as with the pioneering scientists, marketers and sponsors who have brought gene therapies to market.
We know what questions to ask and where to direct them in order to de-risk your strategy.
Our fully tailored research engagements arm you with the knowledge to make better decisions, faster, with 360° of perspective about the market, competitors, payors and patients who will determine your product’s future.
We probe competitors and analogue brands to identify best practices for salesforce sizing, MSL-to-rep ratios, Hub outsourcing, and other go-to-market strategies.
We help marketers navigate small patient populations and their respective advocacy groups, while identifying and building relationships with select KOLs. Additionally, we design and facilitate ad boards to ensure marketing teams are capturing candid feedback and building rapport with a given disease community.
We gather insight into competitors’ trials and provide color commentary on enrollment progress, enrichment, inclusion/exclusion criteria, and protocol amendments — all to support development teams in optimizing their trial design.
We talk with patients, caretakers, parents, HCPs, KOLs, and other stakeholders to lend depth and dimension to the patient journey, while identifying opportunities to accelerate diagnosis, improve access to genetic testing, and get patients on treatment.
We benchmark unique traits in analogue or competitor brand’s Patient Assistance Programs (PAPs) and Specialty Pharmacy Programs such as white glove services, copay assistance, and nurse case managers. We also assess the seamlessness of the patient experience in hybrid insourced/outsourced Hub models.
We pressure test potential RWE metrics and instruments with payors in order to understand the value of specific traits. Further, we survey the literature and KOLs for appropriate novel instruments and explore validation options for use in clinical trials and marketing.
We lead development of all the foundational elements for a comprehensive brand plan, along with corresponding budgets, as your interim brand team.
We survey plans of all sizes, across multiple geographies, to understand how payors perceive your product. This can be done with or without a Test Product Profile (TPP). This approach offers greater flexibility than typical rigid payor ad boards, and can be executed as product characteristics and efficacy emerge.
We actively probe the competitive environment and distill market events into salient takeaways, alerting you in real-time when threats emerge. We go beyond earnings calls, SEC filings, investor conferences, and academic congresses by following up with knowledgeable sources to understand the event and how it impacts your brand.
We determine the feasibility and strategic prioritization of your indication pursuits based on the competitive landscape now and at anticipated trial completion.
We conduct regularly scheduled check-ins with a stable group of disease area stakeholders that serve as an early warning system on new payor policies, investigator-led studies, forthcoming publications, changes in treatment guidelines, and other factors impacting your brand development and strategy.
Learn how we’ll help you make more informed decisions, faster, with a custom, in-depth research plan.
